MedTrace Logo

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-20

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.

The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels.

EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Conditions

  • Aging
  • Frailty
  • Exercise Tolerance
  • Healthy Male and Female Subjects

Interventions

DIETARY_SUPPLEMENT

Placebo

Organoleptically matched inert control.

DIETARY_SUPPLEMENT

NMN, betaine, low-dose hydrogen peroxide (EGA)

Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.

DIETARY_SUPPLEMENT

Nicotinamide Mononucleotide (NMN)

Conventional NMN supplement.

Sponsors & Collaborators

  • Concordia University Chicago

    collaborator OTHER

  • Scott Silveira

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-21
Primary Completion
2026-12-30
Completion
2027-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07144527 on ClinicalTrials.gov